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Background: Recent evidence suggests that a majority of RNAs in the genome do not code for proteins. They are
located in the sense (S) or antisense (AS) orientation and, to date, the functional significance of these non-coding
RNAs (ncRNAs) is poorly understood. Here, we examined the relationship between S and AS transcripts in the
regulation of a key angiogenesis gene, Delta-like 4 (Dll4).
Methods: Rapid Amplification of cDNA Ends (RACE) method was used to identify natural antisense transcripts in
the Dll4 gene locus in murine and human endothelial cells, referred to as Dll4 Anti-Sense (Dll4-AS). Messenger
RNA (mRNA) levels of Dll4 and Dll4-AS were quantified by real-time PCR. The function of Dll4-AS was investigated
by overexpression and knocking down of Dll4-AS.
Results: Dll4-AS comprises of three isoforms that map proximal to the Dll4 promoter region. Expression patterns
of Dll4-AS isoforms vary among different endothelial cell lines, but are always congruent with those of Dll4. A dual
promoter element in the Dll4 locus has been identified that controls the expression of both transcripts. Both Dll4-AS
and Dll4 are sensitive to cellular density in that higher cellular density favors their expression. Exogenous Dll4 stimuli
such as VEGF, FGF and Notch signaling inhibitor altered both DLL4-AS and DLL4 expression suggesting co-regulation of
the transcripts. Also, knocking down of Dll4-AS results in down-regulation of Dll4 expression. As a consequence,
endothelial cell proliferation and migration increases in vitro, and sprout formation increases. The regulation of
Dll4 by Dll4-AS was also conserved in vivo.
Conclusion: A novel form of non-coding RNA-mediated regulation at the Dll4 locus contributes to vascular
developmental processes such as cell proliferation, migration and sprouting.
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Recent findings demonstrate that a new class of RNA
arising from intergenic or introns of vascular specific
genes participate in the regulation of angiogenesis, the
growth of new blood vessels from existing vasculature
[1-3]. These RNAs are referred to as non-coding RNAs
(ncRNAs) because majority of ncRNAs in the genome
do not code for proteins [4]. NcRNAs are classified as
long (>200 bp) (lncRNAs) or short (<200 bp) (sncRNAs)
based on their sizes [5]. Recent evidence suggests that
they are located in the sense (S) or antisense (AS)* Correspondence: rramchan@mcw.edu
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unless otherwise stated.orientation [6,7] and, to date, the functional significance
of these ncRNAs is poorly understood. Previous work
from our laboratory identified a non-coding RNA in the
antisense direction to the tie1 locus, which participates
in the regulation of the tie1 mRNA [1] during embryonic
vascular development. However, we noted that only a
small but significant proportion of embryos displayed
tie1 loss-of-function phenotype. Therefore, we hypothe-
sized that compared to recessive genes, haploinsufficient
genes such as Vegf [8] and Delta-like4 (Dll4) [9] are
tightly regulated during vascular development by antisense
RNA. We focused here on Dll4, an arterial endothelial
specific ligand for Notch1 receptor [10]. We investigated
whether antisense RNA exists in the Dll4 locus, and
whether they had a functional relevance to Dll4 mRNAis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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specific ligand for Notch1 receptor [10], and is a vascular-
specific haploinsufficient gene [9], in that loss of one copy
causes phenotype. Dll4 plays a paramount role in angio-
genesis; and altered Dll4 levels during mouse development
caused vascular malformations, leading to lethality [9]. In
this study, we have identified lncRNAs at the Dll4 locus.
They are transcribed anti-sense to Dll4, and therefore, we
refer to these transcripts as Delta-like4 antisense (Dll4-AS).
Both Dll4 and Dll4-AS transcripts share a common pro-
moter element in the Dll4 genomic locus. Further, we iden-
tify that Dll4-AS regulates Dll4 mRNA levels in vitro, and
this regulation has functional consequences.
Methods
Identification of Dll4-AS
PolyA RNAs were isolated from mouse endothelial cell
line, MS1 using a Poly(A)Purist Kit (Life Technologies,
AM1916). FirstChoice RLM-RACE Kit (Life Technologies,
AM1700) was used to obtain the full length sequences of
Dll4-AS. The RACE primers were derived from the cDNA
sequence of Gm14207 (Accession No. NR_030683). RACE
primers were cctcttcccttaggagtgtgtcctctgt (5′ outer), aggt
ggcctctggttgtcttcatgt (5′ inner), ctcggcttttcctcatacctc
(3′ outer) and tgtccactgtctggttgctc (3′ inner).
Subcellular localization of Dll4-AS
NE-PER Nuclear and Cytoplasmic Extraction Kit (Thermo
Scientific #78833) was used to separate nuclei and cyto-
plasm of MS1 cells. The separated two parts were subjected
to TRIzol extraction, followed by reverse transcription.
Xist served as positive control for nuclear compart-
ment and tRNA-Met for cytoplasmic compartment. The
primers were Xist-for, tgcgggttcttggtcgatgt, Xist-rev, cgcttg
agatcagtgctggc; tRNA-Met-for, ggcccataccccgaaaac, tRNA-
Met-rev, acgggaaggatttaaaccaa.
Quantitative PCR
Total RNA from cultivated cells was extracted by TRIzol
reagent followed by DNase I treatment for 2 h at 37°C.
The DNA-free RNA was further purified using RNAeasy
Mini kit (Qiagen, 74104). RNA concentrations were
measured by Nanodrop (Thermo Scientific), followed
by reverse transcription by SuperScript III (Life Sciences).
Quantitative PCR was carried out with SYBR Green I
in iQ5 Multicolor Real-Time PCR Detection System
(Bio-Rad, 170–9780). The expression levels were normal-
ized to internal βactin or CD31. Primers for mouse βactin,
Dll4-AS1, −AS2, −AS3, total Dll4-AS and Dll4 were:
βactin-for, ctcttttccagccttccttct, βactin-rev, aggtctttacgga
tgtcaacg; AS1-for, ttctcaaaaactccgctgct, AS1-rev,ctctgctct
ttcccctcctc; AS2-for, atccgacgccttaacctttc, AS2-rev,ctccgt
tctgctcctattgc; AS3-for, cccgaaaccttgacttttca, AS3-rev, ccac
cagaggataggagggta; ASt-for, gaggcaataggagcagaacg, ASt-rev,gccaggttgttcagtcaaga; Dll4-for, cagagacttcgccaggaaac,
Dll4-rev, actgcagatgacccggtaag. Primers for human CD31,
DLL4 and DLL4-AS were: CD31-for, tgaacctgtcctgctccatc,
CD31-rev, ccgactttgaggctatcttgg; DLL4-for, actgtgcccgta
acccttg, DLL4-rev, tggagaggtcggtgtagcag; and DLL4-AS-for,
agatgccttgtgtgggacta, DLL4-AS-rev, cctctctcaactccaaatcctg.
Promoter reporter gene assay system
DNA fragments mapped to Dll4 promoter regions were
cloned into pGL4.14 vector (Promega, E6691) using In
Fusion cloning system (Clontech, 638909). pGL4.14 con-
structs containing different inserts were mixed with pRL-TK
Vectors (Promega, E2241) at 20/1 for co-transfecting MS1
cells. Before luciferase activity was determined, the cells
were re-plated onto 24-well plate so that the cellular density
reached 90% confluence at the time point of assay. Follow-
ing the addition of 200 μL 1X reporter lysis buffer into each
well, the plate was placed at −80°C for 30 min and then
equilibrated at room temperature. The cellular lysate was
centrifuged at maximum speed for 1 min. Cleared lysates
were used to measure luciferase and renilla activity on
GloMax® 20/20 Luminometer (Promega, E5331) by Dual-
Luciferase Reporter Assay System (Promega, E1910).
Overexpression of Dll4-AS
pTracer™-CMV2 Vector (Life technologies, V885-01) was
digested with EcoRV and NotI for sub-cloning Dll4-AS
isoforms. Dll4-AS1, −AS2 and -AS3 were amplified from
MS1 cDNA using Phusion DNA polymerase and the
primers harbored NotI site at the 3′ end. The plasmid
contained a separate cassette encoding green fluorescent
protein (GFP) -Zeocin expression that allowed for stable
selection of transfected cells. Transfection of the plasmids
was performed according to the protocol of Lipofecatmine
2000 (Life technologies, 11668027). The cells were
selected by Zeocin, and cells overexpressing Dll4-AS were
tracked through GFP expression.
Dll4-AS knockdown
Vector-Based miRNA and synthetic siRNA were used to
knockdown Dll4-AS expression in both MS1 and EOMA
cells. pcDNA6.2-GW/EmGFP-miR (Life technologies,
K4936-00) was used to express miRNA targeting the
common last exon of all Dll4-AS isoforms. The inside
single-stranded DNA oligonucleotides encoding the tar-
get pre-miRNA and the complementary oligonucleotides
for miR1 are tgctgaggttgttcagtcaagaacctgttttggccactgactgac
aggttcttctgaacaacct and cctgaggttgttcagaagaacctgtcagtcagt
ggccaaaacaggttcttgactgaacaacctc, respectively. Those for
miR2 are tgctgctctgattagatccattcaaggttttggccactgactgaccttg
aatgtctaatcagag and cctgctctgattagacattcaaggtcagtcagtggcc
aaaaccttgaatggatctaatcagagc, respectively. The forward
and reverse synthetic siRNAs for control, siRNA1 and
siRNA2 are ggugagccguguagaguaatt, uuacucuacacggcucacctt,
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ugauaagguutt, aaccuuaucacaggccucctt, respectively.Immunostaining
MS1 cells were plated on sterile glass coverslips placed in
the wells of a culture plate and allowed to adhere over-
night. Cells on coverslips were transfected with siRNAs.
48 h later, the coverslips were removed from the well,
washed in TBS [50 mM Tris · HCl (pH 7.4), 150 mM
NaCl], and fixed in 4% (wt/vol) paraformaldehyde for
10 min before permeabilization in 0.2% (vol/vol) Triton
X-100 for 5 min. Cells were blocked in PBS with 1% goat
serum and 0.1% Tween for 1 h at room temperature
before staining with goat anti-mouse DLL4 (R&D, AF1389).
Following 45 min incubation, cells were washed in
TBS, followed by incubation with a fluorescent-conjugated
IgG secondary antibody for 30 min in dark. After
staining, coverslips were mounted in VectaShield con-
taining DAPI.Mouse studies
Care of the mice during experimental procedures was con-
ducted in accordance with the policies of the Biomedical
Resource Center, Medical College of Wisconsin, and the
National Institutes of Health guidelines for the care and
use of laboratory animals. Protocols had received prior
approval from the Medical College of Wisconsin Insti-
tutional Animal Care and Use Committee. C57BL/6
mice were obtained from Charles River Laboratories
(Franklin, CT). Six day-old C57BL/6 mouse pups were
injected intraperitoneally with 1 mg/kg ultrapure LPS
(Invivogen, CA) or saline and lungs were harvested after
18 h following sacrifice of animals. RNA was obtained
from whole lung using the PureLink RNA kit from Life
Technologies (Carlsbad, CA).Cell proliferation assay
Cell proliferation was performed using an ELISA kit
(Roche # 11647229001). 5 × 103 cells were inoculated
into 96-well culture plate and cells were allowed to at-
tach for 12 h. siRNA-lipid complexes containing 1 pmol
mixed siRNA and 0.3 μl Lipofectamine RNAiMAX was
added into each well. Medium was refreshed 48 h later
and 10 μl BrdU labeling solution was added into it. 12 h
later, the labeling medium was replaced by 200 μl FixDenat
and incubated for 30 min at room temperature. The
FixDenat was replaced by 100 μl anti-BrdU-POD working
solution. 90 min later, the wells were washed 3 times with
PBS. 100 μl substrate solution was added into each well.
Photometric detection was performed 20 min later by
SpectraMax 340PC384 Microplate Reader (Molecular
Devices).Cell migration assay
EOMA cells were plated onto a 6-well plate. After the cells
adhered to the plate surface, control or mixed Dll4-AS
siRNA were introduced into the cells by Lipofectamine
RNAiMAX. 48 h later, the cells were plated onto transwell
inserts at 4 × 104 cells/well in 500 μL of medium. The
transwell inserts were then inserted into a 24-well plate
containing 750 μL of medium. Cells were allowed to mi-
grate at 37°C, 5% CO2 for 2 h. Cells were then fixed at 4%
PFA at RT for 20 min, and were further stained for 5 min
with crystal violet (Sigma) in 2% ethanol and then rinsed in
water. The cells on the upper side of the inserts were re-
moved with a cotton swab, and the cells on the lower side
of the inserts that were counted under light microscopy.
Data are expressed as the mean ± S.D. of 3 independent
assays.
Spheroid sprouting assay
MS1 cells in Dulbecco’s modified Eagle medium (DMEM)
were suspended in hanging drops (300 cells/30 μL) on the
underside of petridish lids. The hanging drops were incu-
bated for 24 h to form spheroids. Harvested spheroids
were suspended in 1.5% collagen gel, and the spheroids-
containing collagen gel was rapidly transferred into
96-well plates pre-coated with the same collagen gel
and allowed to polymerize at 37°C for 30 min. DMEM
containing 30 ng/mL recombinant mouse VEGF was
added to the plates to cultivate the cells for 7 days.
Sprouting vessels were quantified under microscope
by counting the sprouts that had grown out of each
spheroid.
Results
Identification and characterization of Dll4-AS
We searched the mouse genome databases for non-coding
RNAs at Dll4 locus, and found a predicted gene 14207
(Gm14207, Accession No. NR_030683). A cDNA clone
containing Gm14207 was identified from the mouse
thymus, and because Dll4 is expressed in both thymus
and vasculature [11], we investigated the expression pat-
tern for Gm14207 in endothelial cells (ECs). RT-PCRs
based on the Gm14207 sequence was performed, and
PCR products of different sizes were amplified in mouse
pancreatic endothelial cell line MS1. Rapid Amplification
of cDNA Ends (RACE) identified three transcripts anti-
sense to the Dll4 locus in mouse ECs (Figure 1). We
named these transcripts Delta-like 4 antisense1 (Dll4-AS1),
Delta-like 4 antisense2 (Dll4-AS2), Delta-like 4 antisense3
(Dll4-AS3) with lengths of 558 bp, 720 bp and 687 bp,
respectively. The sequences are deposited in GenBank
(Accession numbers: KP171170, KP171171 & KP171172).
To localize Dll4-AS transcripts in cellular compartments,
we used NE-PER Kit (Thermo Scientific) to separate cyto-
plasmic and nuclear RNAs, and performed RT-PCR using
Figure 1 Identification of Dll4-AS isoforms. (A) RACE reactions mapped the Dll4-AS into Dll4 promoter region. Blue and red arrowheads
indicate transcriptional orientations of Dll4-AS and Dll4, respectively. Horizontal black arrowheads indicate following primers’ locations. Vertical
black and grey arrows indicate following siRNA and miRNA targets, respectively. (B) Dll4-AS is enriched in cellular cytoplasm. (C) Dll4-AS expression
coincides with Dll4 in different cell lines. Bend.3: mouse endothelial cell from cerebral cortex; EOMA: mouse endothelial cell from hemangioendothelioma;
MAE: Mouse Aortic Endothelial cell; MBE: Mouse Brain capillary Endothelial cell; MS1: mouse endothelial cell from pancreas; sMHEC: Mouse
Heart Endothelial Cells.
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Dll4-AS transcripts were localized in both cytoplasm
and nucleus of mouse ECs (Figure 1B). Subsequently,
we examined the expression levels of Dll4-AS and Dll4
in different mouse endothelial cell lines (Bend.3: mouse
endothelial cell from cerebral cortex; EOMA: mouse
endothelial cell from hemangioendothelioma; MAE:
Mouse Aortic Endothelial cell; MBE: Mouse Brain capil-
lary Endothelial cell; MS1: mouse endothelial cell from
pancreas; sMHEC: Mouse Heart ECs). We found that
Dll4-AS level differs dramatically among the tested cell
lines. However, comparing across cell lines the trend is
the same in that Dll4-AS levels are congruent with
Dll4 (Figure 1C). To identify human DLL4-AS, we
searched for transcripts at human DLL4 promoter region
in the UCSC Genome Browser. Item 3619762 of Affyme-
trix Exon Array from ENCODE/UW was retrieved and
validated by RT-PCR. The transcript was extended to
768 bp by tiling PCR (Additional file 1: Figure S1).
Dll4-AS shares a common promoter with Dll4
To identify the genomic element that drives Dll4-AS
expression, we cloned DNA fragments near the tran-
scription start site of Dll4-AS into a promoter reporter
vector, pGL4.14 (Figure 2A). Those fragments were placed
in different directions, corresponding to either Dll4-AS or
Dll4 transcription into the vector, and co-transfected with
renilla construct into MS1 cells. Fragments A and A’ were
in the antisense (Dll4-AS) direction, while fragmentsB and B’ were in the Dll4 sense direction. Lysates were
generated, and luciferase gene readouts were measured.
Fragment B and B’ showed the most activity when com-
pared to A and A’. Interestingly, A’ and B’ is the same frag-
ment in opposite direction, and show promoter activity in
both directions. These results indicate that the promoter
of Dll4-AS is the same region as that of Dll4 (Figure 2B),
and imply that the two transcripts share the same pro-
moter region, and drives RNA transcription in both
directions.
Dll4-AS expression is concomitant with Dll4 mRNA
expression
Because Notch-Delta signaling pathway has been exten-
sively implicated in cell-cell contact signaling, we inves-
tigated the expression of Dll4-AS and Dll4 mRNA levels
in different confluent states of MS1 cells. Cells in 100%
confluent state (dense) showed high levels of Dll4-AS,
and Dll4 mRNA levels, and this increase was observed
as the confluency increased from 4-100%. Consistently,
we observed three things. First, that Dll4 expression is
a log higher than Dll4-AS. Second, differences are observed
within each of the three Dll4-AS transcripts across
confluency stages, and third that both RNA levels
change positively (Figure 3A). To investigate whether
Dll4 and Dll4-AS RNAs are co-regulated, we treated
90% confluent MS1 cells with increasing concentra-
tions of DAPT, a notch inhibitor (Figure 3B), or human
umbilical vein (Figure 3C) or coronary artery (Figure 3D)
Figure 2 Identification of Dll4-AS promoter. (A) Genomic fragments aligning with both Dll4 and Dll4-AS transcription start sites were cloned
into a promoter reporter vector, pGL4.14. (B) These constructed vectors were mixed with 1/20 (molar ratio) Renilla vector, which serves as internal
control for cell transfection. The transfected MS1 cells were lysed 48 h later for luminescence reading.
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we observed that when DLL4 RNA level increases or
decreases, the DLL4-AS levels increase or decrease
respectively.
To confirm these findings in vivo, we performed experi-
ments in the lung tissues in mice. Mice were treated with
lipopolysaccharide (LPS) and lung tissues were harvested
to analyze levels of Dll4 and Dll4-AS RNA. LPS is known
to induce angiogenesis and modify notch signaling
[12,13]. Lung tissues isolated from LPS-treated neo-
natal mice showed increase in both Dll4 and Dll4-AS
RNA levels (−2 and −3) when compared to control
mice (Figure 3E). The increase in Dll4-AS is less than
that of Dll4, which is consistent with the data from
cultured cells. These results suggest that Dll4AS regu-
lation occurs both in vitro and in vivo, and the regula-
tion is conserved across humans and mice presumably
by a set of factors that bind at the common promoter
region.
Dll4-AS regulates Dll4 expression
We investigated using loss-of-function approaches, the ef-
fect of Dll4-AS on Dll4 RNA levels in ECs. We used
pcDNA6.2-GW/EmGFP-miR vector designed to express
artificial microRNAs (miRNAs). Two artificial miRNAs
that showed 100% homology to the target sequence
and targeting the common regions of Dll4-AS isoforms
were designed. MS1 cells transfected with the two arti-
ficial miRNAs successfully decreased Dll4 mRNA level
(Figure 4A). To exclude the off-target possibility of themiRNAs, we used synthetic short hairpin silencing
RNAs (siRNA) oligonucleotides targeting the common
region of Dll4-AS isoforms. When the siRNAs were
transfected into MS1 cells, Dll4-AS expression dropped
60%. Similarly, Dll4 mRNA decreased roughly 40%
(Figure 4B), which was further validated at the protein
level by immunocytochemistry (Figure 4C). In gain-of-
function experiments, we overexpressed individual Dll4-AS
in MS1 cells. Western blot analysis of MS1 cell lysates
showed that Dll4-AS1 and -AS3 up regulated the DLL4
protein levels (Figure 4D).
Dll4-AS regulates angiogenesis
Because Dll4-AS affects Dll4 mRNA expression, we pos-
tulate that modulating Dll4-AS levels in ECs should
affect EC phenotype. We focused on cell proliferation
and migration, two phenotypes associated with tip vs.
stalk cell formation where Dll4 is known to participate
in [14]. We compared the modulations of Dll4-AS in
two cell lines namely MS1 and hemangioendothelioma
(EOMA) cell line. EOMA cells are extensively used for
vascular anomaly research, a condition associated with
aberrant DLL4 signaling [15]. We performed BrdU-
based proliferation assay in Dll4-AS silenced MS1 cells,
and observed an increase in cellular proliferation (Figure 5A),
which was also observed in EOMA cell line (Figure 5B).
Intriguingly, Dll4-AS silenced EOMA cells showed
increased migration to serum stimulus in the Boyden
chamber assay (Figure 5C). To investigate Dll4-AS
influence on sprout formation and branching, we generated
Figure 3 Dll4-AS responses to exogenous stimuli. (A) Dll4-AS expression coincides with Dll4 in the status of different cellular confluences. Dll4-AS
expression level was measured in 0.8%, 4%, 20% and 100% confluent MS1 cells by quantitative PCRs. (B) DAPT treatment down-regulates the
expression of both Dll4-AS and Dll4 in MS1 cells. (C) HUVECs deprived of serum for 16 h were treated with 50 ng/ml recombinant human VEGF or
FGF for 24 h. DLL4 and DLL4-AS were quantitated by qPCR in these cells. (D) HCAECs deprived of serum for 16 h were treated with 50 ng/ml recombinant
human VEGF or FGF for 24 h. DLL4 and DLL4-AS were quantitated by qPCR in these cells. (E) 6-day old C57/BL6 mice were treated with 1 mg/kg
intraperitoneal LPS. Dll4 and Dll4-AS were quantitated by qPCR in neonatal mouse lungs 18 hr after systemic LPS. *denotes p < 0.05.
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bedded in collagen gel and cultured under VEGF stimulation
conditions. The sprouting vessels that emerged from the
spheroids were analyzed at day 7. On average, 3.9 sprouts
emerged from the spheroids of wild type MS1 cells, whereas
5.7 sprouts emerged from Dll4-AS knockdown [Figure 5D
and E] MS1 cells. This data implies that similar to Dll4,
Dll4-AS also restricts endothelial sprouting. These results
collectively suggest that down-regulation of Dll4-AS and in
turn Dll4 impairs EC proliferation and migration responses,
concepts associated with non-productive angiogenesis
observed previously in Dll4 knockout mice [16].
Discussion
In this study, we have identified lncRNAs at the Dll4
locus. The salient features of this study are: (a) Identifi-
cation of three isoforms of Dll4-AS in murine ECs thatare transcribed in the antisense direction to Dll4, and
share the last exon; (b) Genomic locus of Dll4 contains
cis elements that are responsible for the dual transcrip-
tion of Dll4 and Dll4-AS; (c) Co-regulation of Dll4 and
Dll4-AS transcripts is observed in that loss of Dll4-AS
affects Dll4 mRNA level in vitro and in vivo; and (d)
Down-regulation of Dll4-AS (and in turn Dll4) function-
ally impairs EC proliferation and migration, and enhances
sprout formation. These results collectively implicate a
new level of regulation at the Dll4 gene locus in vascular
development.
LncRNAs are a new class of regulators involved in
genome organization and gene expression, especially in
the process of cell differentiation and organ development
[17]. In contrast to sncRNAs such as miRNAs, which
target multiple coding sequences, lncRNAs usually tar-
get nearby genes [2,18]. Haploinsufficient genes like Dll4
Figure 4 Manipulation of Dll4-AS changes the expression of Dll4. (A) pcDNA6.2-GW/EmGFP-Dll4-AS miR vectors were transfected into MS1
cells. qPCR was performed 48 h later. Synthetic siRNAs were transfected into MS1 cells. qPCR (B) and immunostaining (C) were performed 48 h
later. pTracer-Dll4-AS vectors were transfected into MS1 cells. Western blotting (D) was performed 48 h later.
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monitored because Dll4 is a key modulator of angiogenic
sprouting and branching processes, critical events asso-
ciated with physiological and pathological angiogenesis.
Regulation of Dll4 clearly occurs at the transcriptional
and post-transcriptional levels [19]. Our report here
proposes an additional layer of regulation to include
lncRNAs-mediated Dll4 regulation. Three lncRNA iso-
forms of Dll4-AS were identified with expression levels
for each varying greatly across multiple cell types. The
rationale for mutliple isoforms at this locus is unclear.
Of the three isoforms of Dll4-AS, only Dll4-AS1 over-
laps with Dll4. We hypothesize that these RNAs are
part of the checks and balances in the system for con-
trol of haploinsufficient gene expression.
Antisense ncRNAs arising from promoter regions
can be classified into two categories according to their
location [20]. The first category is composed of anti-
sense ncRNAs overlapping with the corresponding mRNAs
like Dll4-AS1. These antisense ncRNAs have been shown to
down-regulate the corresponding mRNAs via the formation
of ncRNA-mRNA duplexes [21]. The second category is
antisense ncRNAs starting from regions upstream of
the transcription start sites (TSSs) of the correspond-
ing mRNAs, i.e., Dll4-AS2 and -AS3. These antisense
ncRNAs have been shown to functionally up-regulate
the corresponding mRNAs via epigenetic mechanisms
[22]. However, location of lncRNAs do not strictly dic-
tate up or down regulation of cognate transcript. Inour case, in MS1 and EOMA cells, Dll4-AS2 and -AS3
expression are highest compared to Dll4-AS1. Whether
this selective up regulation of the AS isoforms is of
functional consequence is yet to be determined. This
selective up regulation was also noticed in the LPS-
treated lung samples where AS2 and AS3 levels were
up along with Dll4. Intriguingly, in overexpression ex-
periments, Dll4-AS1 and AS3 transfected MS1 cells
showed increased DLL4 protein compared to Dll4-AS2.
Our results collectively suggest that selective combina-
torial expression of Dll4-AS specific isoforms in cells
and tissues control the expression of Dll4.
Genome locus of Dll4 contains a number of cis ele-
ments, which allow transcription factors to bind and con-
trol the expression of Dll4 [23]. Dll4-AS shares a common
promoter region with Dll4, implicating a co-regulatory
mechanism for both RNAs. Gene placement in a
“head-to-head” fashion like that of Dll4 and Dll4-AS
is an ancient and conservative gene organization structure.
The intergenic region between Dll4 and Dll4-AS serves as
a shared promoter, which drives the expression of the
two genes toward opposite directions. This RNA Pol
II-mediated process occurs in almost equal proportion
in both directions [24]. The promoter sequence ultim-
ately decides the dominant transcriptional direction
[25], resulting in more abundant sense transcripts than
antisense transcripts [24]. This is consistent in regards
to the expression levels of Dll4-AS and Dll4, with more
abundant Dll4 mRNA observed in qPCR in cells, and
Figure 5 Cell proliferation and migration assays. (A) MS1 cells in 96-well plate were transfected with 1 pmol synthetic siRNAs. 48 h later,
transfection medium was replaced with regular medium containing BrdU labeling reagent. Incubation lasted for 16 h before proliferation
assay was performed. *denotes p < 0.05 (B) EOMA cells in 96-well plate were transfected with 1 pmol synthetic siRNAs. 48 h later, BrdU labeling solution
was added into medium. Incubation lasted for 16 h before proliferation assay was performed. (C) Cell migration assay. EOMA cells in 6-well plate
were transfected with 25 pmol synthetic siRNA. 48 h later, cells were placed onto trans-well membrane to allow migrate for 2 h. Cells were
counted under microscope. (D) Representative spheroids with sprouting vessels. MS1 cells in 6-well plate were transfected with 25 pmol
synthetic siRNA. 24 h later, cells were suspended in hanging drops to allow cellular aggregation. Spheroids were embedded in collagen gel to culture
for 7 days. (E) Quantification of sprouts growing from the spheroids. 30 spheroids were examined for each transfection. *denotes p< 0.05.
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tion is more active than the antisense direction. Most
bidirectional promoters act as inseparable functional
units that coordinately regulate the transcription of
both genes [26], which is also consistent with our find-
ings. The in vivo experiments on LPS-treated lung
samples also confirm the co-regulatory aspects of this
regulation.
Transcriptional correlation prognosticates functional
association [27], so the function of Dll4-AS is likely to be
pertinent to that of Dll4. In fact, both Dll4-AS and Dll4
are co-expressed in ECs and show a positive correlation.
Correlations between bidirectional transcripts could be
positive or negative depending on differences in the cellu-
lar status [28]. Generally, positively correlated transcripts
function in the same signaling pathway, and are coregu-
lated in a common window of the cell cycle to respond to
inductive signals [29-31]. Therefore, it is not surprising
that down regulation of Dll4-AS downregulates Dll4.
Further, down regulation of Dll4 in mouse causes a
hypersprouting phenotype [9]. However, these sproutsare non-functional, which is referred to as non-productive
angiogenesis [16]. Similarly, when Dll4 is downregulated
due to loss of Dll4-AS, the ECs are hyperproliferative and
hypermigratory, concepts that support non-productive
angiogenesis. Sprouting was enhanced from Dll4-AS
siRNA treated MS1 cells further confirming the similar
functional role for Dll4-AS and Dll4 in angiogenesis.
Whether this regulation leads to differences in tip vs.
stalk cell specification is unknown because Dll4-Notch
is known to actively participate in this process [32].
Similarly, Dll4-AS and Dll4 levels are affected by VEGF
stimulation implying that Dll4-AS regulation of Dll4
may participate in the VEGF-Notch cross talk pathway
during angiogenesis. The factors that govern the regula-
tion of the Dll4-AS transcript expression, and the role of
antisense RNA regulation in specific processes of angio-
genesis are all active areas of investigation in the lab.
Conclusion
In summary, we report here the identification of three
lncRNAs in the antisense direction in the Dll4 locus.
Li et al. Vascular Cell  (2015) 7:3 Page 9 of 9These antisense RNAs are co-regulated with Dll4 RNA
using a common genomic element. Downregulation of
Dll4-AS affects Dll4 levels in ECs, which in turn causes
functional changes to the phenotype of ECs. We con-
clude that Dll4-AS regulation of Dll4 is a novel mechan-
ism of gene expression modulation, which has functional
implications in vascular development.
Additional file
Additional file 1: Figure S1. Schematic representation of DLL4 locus in
Homo sapiens chromosome 15, GRCh38 Primary Assembly. DLL4 mRNA
starting from 40929333 is shown in red boxes; DLL4-AS starting from
40927667 and ending at 40926900 is shown in a blue box.
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